Constance A Benson

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
  2. ncbi request reprint Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America
    Constance A Benson
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    MMWR Recomm Rep 53:1-112. 2004
  3. ncbi request reprint A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086
    Constance A Benson
    University of California, San Diego School of Medicine, San Diego, CA 92103, USA
    J Infect Dis 194:1309-18. 2006
  4. ncbi request reprint Structured treatment interruptions--new findings
    Constance A Benson
    University of California San Diego School of Medicine, San Diego, CA, USA
    Top HIV Med 14:107-11. 2006
  5. pmc Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America
    Steven G Deeks
    University of California San Francisco, San Francisco, San Diego, CA 94110, USA
    Clin Infect Dis 49:1582-90. 2009
  6. ncbi request reprint A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV
    Constance A Benson
    Division of Infectious Disease, University of Colorado Health Sciences Center, Denver, Colorado, USA
    AIDS 18:2269-76. 2004
  7. pmc Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy
    Cara C Wilson
    University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Clin Vaccine Immunol 15:986-94. 2008
  8. pmc The use of pooled viral load testing to identify antiretroviral treatment failure
    Davey M Smith
    University of California San Diego, La Jolla, CA 92093 0679, USA
    AIDS 23:2151-8. 2009
  9. pmc Performance evaluation of the MBio Diagnostics point-of-care CD4 counter
    Cathy Logan
    Division of Infectious Diseases, University of California, 9500 Gilman Drive, MC 0711, San Diego, CA 92093, USA
    J Immunol Methods 387:107-13. 2013
  10. ncbi request reprint Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels
    Carrie A Sailer
    Denver Veterans Affairs Medical Center, Denver, CO 80262, USA
    J Infect Dis 195:734-8. 2007

Research Grants

  1. UCSD Department of Medicine HIV/AIDS Clinical Trials Unit
    Constance Benson; Fiscal Year: 2007
  2. ADULT ACTG CENTRAL GROUP
    Constance Benson; Fiscal Year: 2007

Detail Information

Publications21

  1. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
    ..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed...
  2. ncbi request reprint Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America
    Constance A Benson
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    MMWR Recomm Rep 53:1-112. 2004
    ..Tables address drugs and doses, drug toxicities, drug interactions, adjustment of drug doses in persons with reduced renal function, and data about use of drugs in pregnant women...
  3. ncbi request reprint A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086
    Constance A Benson
    University of California, San Diego School of Medicine, San Diego, CA 92103, USA
    J Infect Dis 194:1309-18. 2006
    ..The role of structured treatment interruption (STI) before optimized antiretroviral therapy (ART) in patients with drug-resistant human immunodeficiency virus type 1 (HIV-1) is uncertain...
  4. ncbi request reprint Structured treatment interruptions--new findings
    Constance A Benson
    University of California San Diego School of Medicine, San Diego, CA, USA
    Top HIV Med 14:107-11. 2006
    ..This article summarizes a presentation on STI made by Constance A. Benson, MD, at the International AIDS Society-USA course in San Francisco in April 2006...
  5. pmc Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America
    Steven G Deeks
    University of California San Francisco, San Francisco, San Diego, CA 94110, USA
    Clin Infect Dis 49:1582-90. 2009
    ....
  6. ncbi request reprint A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV
    Constance A Benson
    Division of Infectious Disease, University of Colorado Health Sciences Center, Denver, Colorado, USA
    AIDS 18:2269-76. 2004
    ..Emtricitabine (FTC) QD is a newly approved nucleoside reverse transcriptase inhibitor compared in this study to twice daily lamivudine (3TC BID)...
  7. pmc Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy
    Cara C Wilson
    University of Colorado Health Sciences Center, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Clin Vaccine Immunol 15:986-94. 2008
    ....
  8. pmc The use of pooled viral load testing to identify antiretroviral treatment failure
    Davey M Smith
    University of California San Diego, La Jolla, CA 92093 0679, USA
    AIDS 23:2151-8. 2009
    ....
  9. pmc Performance evaluation of the MBio Diagnostics point-of-care CD4 counter
    Cathy Logan
    Division of Infectious Diseases, University of California, 9500 Gilman Drive, MC 0711, San Diego, CA 92093, USA
    J Immunol Methods 387:107-13. 2013
    ..This preliminary evaluation suggests that the MBio CD4 device holds promise as a POC system for quantitation of CD4 T cells in limited-resource settings...
  10. ncbi request reprint Whole-blood interleukin-18 level during early HIV-1 infection is associated with reduced CXCR4 coreceptor expression and interferon- gamma levels
    Carrie A Sailer
    Denver Veterans Affairs Medical Center, Denver, CO 80262, USA
    J Infect Dis 195:734-8. 2007
    ..During early HIV-1 infection, IL-18 may regulate HIV-1 coreceptor expression and have antiretroviral activity...
  11. ncbi request reprint Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients
    Constance A Benson
    Department of Medicine, University of Colorado Health Sciences Center, 4200 E 9th Avenue, B 168, Denver, CO 80262, USA
    J Infect Dis 185:599-607. 2002
    ..Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events...
  12. ncbi request reprint A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome
    Constance A Benson
    Division of Infectious Diseases, University of Colorado Health Sciences Center, Denver, USA
    Clin Infect Dis 37:1234-43. 2003
    ..057). Subjects in the C+E+R group had improved survival, compared with the C+E group (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.23-0.83) and the C+R group (HR, 0.49; 95% CI, 0.26-0.92)...
  13. doi request reprint Tuberculosis due to Mycobacterium bovis in patients coinfected with human immunodeficiency virus
    Daniel Park
    Division of Infectious Diseases, University of California, San Diego, California, USA
    Clin Infect Dis 51:1343-6. 2010
    ..Patients with M. bovis infection were more likely to have advanced immunosuppression (CD4 T cell counts ≤200 cells/μL). Hispanic ethnicity, male sex, and abdominal disease were strongly associated with M. bovis disease...
  14. ncbi request reprint Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial
    Kathleen Mulligan
    Department of Medicine, University of California, San Francisco, California 94110, USA
    J Clin Endocrinol Metab 92:563-70. 2007
    ..Reduced energy intake is a primary factor in HIV-associated wasting. Megestrol acetate (MA) stimulates appetite and weight gain. However, much of the weight gained is fat, possibly as a result of MA-induced hypogonadism...
  15. pmc Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186
    John G Gerber
    Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 47:459-66. 2008
    ..AIDS Clinical Trials Group A5186 examined the safety and efficacy of fish oil plus fenofibrate in subjects not achieving serum TG levels < or =200 mg/dL with either agent alone...
  16. ncbi request reprint Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel
    Morris Schambelan
    University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA
    J Acquir Immune Defic Syndr 31:257-75. 2002
    ..These recommendations were developed to guide physicians actively involved in HIV care in the management of metabolic complications that occur primarily within the context of potent antiretroviral therapy...
  17. pmc AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics
    Marlene Smurzynski
    Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    HIV Clin Trials 9:269-82. 2008
    ..We describe the rationale, design, and baseline characteristics of the ALLRT cohort and its potential to address important research questions related to ARV therapy...
  18. ncbi request reprint Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study
    David W Haas
    Center for Human Genetics Research, Vanderbilt University, Nashville, TN, 37203, USA
    J Infect Dis 194:1098-107. 2006
    ..Immune recovery during antiretroviral therapy is a complex phenotype that is influenced by multiple genetic variants. Future studies should validate these tentative associations and define underlying mechanisms...
  19. doi request reprint Cross-sectional study of endothelial function in HIV-infected patients in Brazil
    Ana Cristina O Andrade
    Bahian School of Medicine and Public Health, Bahia, Brazil
    AIDS Res Hum Retroviruses 24:27-33. 2008
    ..This dysfunction may contribute to the risk for HIV-associated atherosclerosis...
  20. pmc Prevalence and factors associated with dry skin in HIV infection: the FRAM study
    Daniel Lee
    Department of Medicine, University of California San Diego, CA, USA
    AIDS 21:2051-7. 2007
    ..Complaints of dry skin in HIV-infected individuals were reported after the advent of HAART. The objective of the study was to evaluate the prevalence of dry skin and associated factors in HIV-infected and control subjects...
  21. ncbi request reprint Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy
    Ronald J Bosch
    Center for Biostatistics in AIDS Research, Harvard University School of Public Health, Boston, MA 02115, USA
    J Acquir Immune Defic Syndr 44:268-77. 2007
    ..To examine pretreatment factors associated with longer term (144 weeks) responses to antiretroviral therapy (ART)...

Research Grants5

  1. UCSD Department of Medicine HIV/AIDS Clinical Trials Unit
    Constance Benson; Fiscal Year: 2007
    ..The outcome of the proposed research will contribute substantially to halting the spread of HIV/AIDS and to improving the lives of those already infected with HIV-1. ADMINISTRATIVE COMPONENT: ..
  2. ADULT ACTG CENTRAL GROUP
    Constance Benson; Fiscal Year: 2007
    ..Appendices include the by-laws, SOPs, selected publications, international collaborations, and annual reports. ..